Gilead's Kite To Buy Tmunity, Enhancing CAR-T Pipeline And Manufacturing

Kite CEO Christie Shaw said Tmunity brings three advantages: armored CAR-Ts, manufacturing technology and an ongoing research deal with the University of Pennsylvania.

holding hands — Kite is buying Tmunity • Source: Shutterstock

Gilead Sciences, Inc.'s Kite cell therapy unit is expanding through external investment, with the company announcing on 20 December that it will acquire privately held Tmunity Therapeutics Inc. for an undisclosed amount to develop next-generation chimeric antigen receptor T-cell (CAR-T) therapies.

The latest deal complements another recent business development deal by Kite with Arcellx, Inc. to co-develop and commercialize an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

13 Jun 2025

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

BioNTech To Buy mRNA Rivals CureVac

12 Jun 2025

• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.